Apr. 20 at 3:31 PM
$TARS I added heavily in the 65 range. It reminds me a little bit of SLNO, first and only drug approved, no competition in sight and focus solely on one API.
However, clear study results, no short report, china approval and a very likely EU approval by 2027, near-term pipeline catalysts (which are not baked into the mcap btw) and in addition, a very conservative management guidance in place, suggesting 2b revenue with Xdemvy, while the EV is sitting at ~ 2.4b$.
Needless to say, there were around 4-5 parties interested in SLNO's Vykat over the course of the launch year, of course, some of them withdraw, but I believe that commercial success stories without competition get pretty surely bought out at a certain timepoint (not the investment thesis here, just cherry on the top).
